← Human Trials & Peer-Reviewed Studies
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
Plain-language guide to PMID 27106272 (2016): randomized controlled trial study of Exenatide in 44 subjects.
Key Facts
- PMID
- 27106272
- Journal
- Diabetes, obesity & metabolism
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Dutour A et al. (14 authors)
- DOI
- 10.1111/dom.12680
- Registered trial
- NCT02042664
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exenatide, published as a randomized controlled trial.
To conduct a prospective randomized trial to investigate the effect of glucagon-like peptide-1 (GLP-1) analogues on ectopic fat stores.
Who Took Part
According to the abstract, 44 subjects were involved.
By PubMed's age tags, the people studied were middle-aged adults, both men and women.
A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The methods mention a period of 26 weeks.
What Was Measured
PubMed files the paper under topics including Adipose Tissue, Diabetes Mellitus, Type 2, Exenatide, Fatty Liver, Glycated Hemoglobin, Heart and Hypoglycemic Agents.
The authors tagged it with the keywords epicardial adipose tissue, glucagon-like peptide 1 receptor agonist, hepatic triglyceride content, magnetic resonance imaging, myocardial triglyceride content and obesity.
What This Means in Plain Language
The paper is a randomized study of Exenatide in 44 subjects over 26 weeks.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2016 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Exenatide compound page.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.